Quanterix Corp (OQ:QTRX)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 900 Middlesex Turnpike
BILLERICA MA 01821
Tel: N/A
Website: https://www.quanterix.com
IR: See website
<
Key People
Masoud Toloue
President, Chief Executive Officer, Director
Vandana Sriram
Chief Financial Officer
 
Business Overview
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
Financial Overview
For the fiscal year ended 31 December 2023, Quanterix Corp revenues increased 16% to $122.4M. Net loss decreased 67% to $32.3M. Revenues reflect Product revenue segment increase of 14% to $79.5M, Service and other revenue segment increase of 17% to $40.3M. Lower net loss reflects Interest Expense/Income - Net increase from $5.1M to $15.8M (income), Selling, General & Administrative Expens decrease of 3% to $77.1M (expense).
Employees: 441 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $294.45M as of Dec 31, 2023
Annual revenue (TTM): $122.37M as of Dec 31, 2023
EBITDA (TTM): -$41.80M as of Dec 31, 2023
Net annual income (TTM): -$32.33M as of Dec 31, 2023
Free cash flow (TTM): -$22.69M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 38,247,078 as of Apr 5, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.